Terconazole Vaginal Suppositories, 80 mg is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida , the diagnosis should be confirmed by KOH smears and/or cultures.
One Terconazole Vaginal Suppository (80 mg terconazole) should be administered intravaginally once daily at bedtime for three consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of terconazole vaginal suppositories is not affected by menstruation.
www.fda.gov/medwatchRx Only
Terconazole Vaginal Suppositories are white to off-white suppositories for intravaginal administration containing 80 mg of the antifungal agent terconazole, cis-1-[ p-[[2-(2,4-Dichlorophenyl)-2-(1 H-1,2,4-triazol-1-ylmethyl)-1, 3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, in triglycerides derived from coconut and/or palm kernel oil (a base of hydrogenated vegetable oils) and butylated hydroxyanisole.
The structural formula of terconazole is as follows:
 | TERCONAZOLE
C 26H 31Cl 2N 5O 3 |
Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.
Following a single intravaginal application of a suppository containing 240 mg 14C-terconazole to healthy women, approximately 70% (range: 64 to 76%) of terconazole remains in the vaginal area during the suppository retention period (16 hours); approximately 10% (range: 5 to 16%) of the administered radioactivity was absorbed systemically over 7 days. Maximum plasma concentrations of terconazole occur 5 to 10 hours after intravaginal application of the cream or suppository. Systemic exposure to terconazole is approximately proportional to the applied dose, whether as the cream or suppository. The rate and extent of absorption of terconazole are similar in patients with vulvovaginal candidiasis (pregnant or non-pregnant) and healthy subjects.
Terconazole is highly protein bound (94.9%) in human plasma and the degree of binding is independent of drug concentration over the range of 0.01 to 5.0 mcg/mL.
Systemically absorbed terconazole is extensively metabolized (>95%).
Across various studies in healthy women, after single or multiple intravaginal administration of terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours. Following a single intravaginal administration of a suppository containing 240 mg 14C-terconazole to hysterectomized or tubal ligated women, approximately 3 to 10% (mean ± SD: 5.7 ± 3.0%) of the administered radioactivity was eliminated in the urine and 2.0 to 6% (mean ± SD: 4.2 ± 1.6%) was eliminated in the feces during the 7-day collection period.
There is no significant increase in maximum plasma concentration or overall exposure (AUC) after multiple daily applications of the cream for 7 days or suppositories for 3 days.
Photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2% and 0.8% creams under conditions of filtered artificial ultraviolet light.
Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients who were treated with terconazole suppositories or vaginal cream (0.4% and 0.8%).
Terconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of terconazole. Mammalian cell demethylation is less sensitive to terconazole inhibition.
Terconazole exhibits antifungal activity in vitroagainst Candida albicansand other Candidaspecies. The MIC values of terconazole against most Lactobacillusspp. typically found in the human vagina were ≥128 mcg/mL; therefore these beneficial bacteria are not affected by drug treatment.
Terconazole Vaginal Suppositories, 80 mg is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.
Patients known to be hypersensitive to terconazole or to any of the components of the suppositories.
Anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy. Terconazole therapy should be discontinued if anaphylaxis or toxic epidermal necrolysis develops.
For vulvovaginal use only. Terconazole is not for ophthalmic or oral use. Discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.
The base contained in the suppository formulation may interact with certain rubber or latex products, such as those used in vaginal contraceptive diaphragms or latex condoms; therefore concurrent use is not recommended.
If there is lack of response to terconazole, appropriate microbiologic studies (standard KOH smear and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.
The therapeutic effect of this product is not affected by oral contraceptive usage.
Studies to determine the carcinogenic potential of terconazole have not been performed.
Terconazole was not mutagenic when tested in vitrofor induction of microbial point mutations (Ames test), or for inducing cellular transformation, or in vivofor chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells.
No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day for a three month period.
There was no evidence of teratogenicity when terconazole was administered orally up to 40 mg/kg/day (25× the recommended intravaginal human dose of the suppository formulation) in rats, or 20 mg/kg/day in rabbits, or subcutaneously up to 20 mg/kg/day in rats.
Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20 to 40 mg/kg. In rats, this was reflected as a decrease in litter size and number of viable young and reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal variants.
The no-effect dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/mL which exceeds by 17 times the mean peak plasma level (0.010 mcg/mL) seen in normal subjects after intravaginal administration of terconazole 80 mg vaginal suppository. This safety assessment does not account for possible exposure of the fetus through direct transfer to terconazole from the irritated vagina by diffusion across amniotic membranes.
Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the physician considers it essential to the welfare of the patient.
Terconazole may be used during the second and third trimester if the potential benefit outweighs the possible risks to the fetus.
It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days, but overall pup weight and weight gain were comparable to or greater than controls throughout lactation. Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and efficacy in children have not been established.
Clinical studies of terconazole vaginal suppositories did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
During controlled clinical studies conducted in the United States, 284 patients with vulvovaginal candidiasis were treated with terconazole 80 mg vaginal suppositories. Based on comparative analyses with placebo (295 patients), the adverse experiences considered adverse reactions most likely related to terconazole 80 mg vaginal suppositories were headache (30.3% vs. 20.7% with placebo) and pain of the female genitalia (4.2% vs. 0.7% with placebo). Adverse reactions that have also been reported but were not statistically significantly different from placebo were burning (15.2% vs. 11.2% with placebo) and body pain (3.9% vs. 1.7% with placebo). Fever (2.8% vs. 1.4% with placebo) and chills (1.8% vs. 0.7% with placebo) have also been reported. The adverse drug experience on terconazole most frequently causing discontinuation was burning (2.5% vs. 1.4% with placebo) and pruritus (1.8% vs. 1.4% with placebo).
The following adverse drug reactions have been first identified during post-marketing experience with terconazole:. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General: Asthenia, Influenza-Like Illness consisting of multiple listed reactions including fever and chills, nausea, vomiting, myalgia, arthralgia, malaise
Immune: Hypersensitivity, Anaphylaxis, Face Edema
Nervous: Dizziness
Respiratory: Bronchospasm
Skin: Rash, Toxic Epidermal Necrolysis, Urticaria
To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
In the rat, the oral LD 50values were found to be 1741 and 849 mg/kg for the male and female, respectively. The oral LD 50values for the male and female dog were ≅1280 and ≥640 mg/kg, respectively.
In the event of oral ingestion of suppository or cream, supportive and symptomatic measures should be carried out. If the cream is accidentally applied to the eyes, wash with clean water or saline and seek medical attention if symptoms persist.
One Terconazole Vaginal Suppository (80 mg terconazole) should be administered intravaginally once daily at bedtime for three consecutive days.
Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of terconazole vaginal suppositories is not affected by menstruation.
Terconazole Vaginal Suppositories 80 mg are available as 2.5 g, elliptically-shaped white to off-white suppositories in packages of three with a vaginal applicator. NDC 0713-0552-73
Store at 20°- 25°C (68°- 77°F)[see USP Controlled Room Temperature].
Distributed by:
Cosette Pharmaceuticals, Inc.
South Plainfield, NJ 07080
Revised: 02/2021
8-0552CPLNC1/VC7476
Terconazole Vaginal
Suppositories 80 mg
Three oval suppositories, for use inside the vagina only.
Designed to be inserted into the vagina.
HOW TO USE:
Place one suppository into the vagina each night at bedtime, for 3 nights, as directed by your doctor. The terconazole vaginal suppository is self-lubricating and may be inserted with or without the applicator.
A. Insertion
withthe applicator
1. Filling the applicator
|
|
2. Using the applicator
3. Cleaning the applicator
After each use, you should thoroughly clean the applicator by following the procedure below:
B. Insertion withoutthe applicator
NOTE: Store the suppositories at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature]. See end flap of carton or suppository label for lot number and expiration date.
A WORD ABOUT YEAST INFECTIONS
Why do yeast infections occur?
Yeast infections are caused by an organism called Candida(KAN di duh). It may be present in small and harmless amounts in the mouth, digestive tract, and vagina. Sometimes the natural balance of the vagina becomes upset. This may lead to rapid growth of Candida,which results in a yeast infection. Symptoms of a yeast infection include itching, burning, redness, and an abnormal discharge.
Your doctor can make the diagnosis of a yeast infection by evaluating your symptoms and looking at a sample of the discharge under the microscope.
How can I prevent yeast infections?
Certain factors may increase your chance of developing a yeast infection. These factors don't actually cause the problem, but they may create a situation that allows the yeast to grow rapidly.
Controlling these factors can help eliminate yeast infections and may prevent them from coming back.
Some other helpful tips:
1.For best results, be sure to use the medication as prescribed by your doctor, even if you feel better quickly.
2.Avoid sexual intercourse, if your doctor advises you to do so. The suppository formulation (not the cream) may damage the diaphragm or latex condom. Therefore, use of the diaphragm or latex condom during therapy with the suppository is not recommended. Consult your physician.
3.If your partner has any penile itching, redness, or discomfort, he should consult his physician and mention that you are being treated for a yeast infection.
4.You can use the medication even if you are having your menstrual period. However, you should not use tampons because they may absorb the medication. Instead, use external pads or napkins until you have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medication leaks.
5.Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the growth of yeast.
6.Wipe from front to rear (away from the vagina) after a bowel movement.
7.Don't douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal balance.
8.Don't scratch if you can help it. Scratching can cause more irritation and spread the infection.
9.Discuss with your physician any medication you are already taking. Certain types of medication can make your vagina more susceptible to infection.
10.Eat nutritious meals to promote your general health.
Distributed by:
Cosette Pharmaceuticals, Inc.
South Plainfield, NJ 07080
Revised 02/2021
8-0552CPLNC1/VC7476
C™
Terconazole
Vaginal
Suppositories
80 mg
NDC 0713- 0552-73
Rx only
3 SUPPOSITORIES
WITH VAGINAL APPLICATOR
3
Vaginal
Suppositories
Keep this and all medications out of the reach of children.
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a1f2acc3-46a1-8c88-4468-5826c2e9fea6 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0713-0552-73 | EA - Each | 0713-0552 | ee65327c-6294-4e49-863a-19dbcd19f8a5 | 1 | 2015-11-12 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Terconazole | ACTIVE INGREDIENT | 0KJ2VE664U | 1 | |
| Terconazole | ACTIVE MOIETY | 0KJ2VE664U | 1 | |
| butylated hydroxyanisole | INACTIVE INGREDIENT | REK4960K2U | 1 | |
| coconut oil | INACTIVE INGREDIENT | Q9L0O73W7L | 1 | |
| palm kernel oil | INACTIVE INGREDIENT | B0S90M0233 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0713-0552 | 0713-0552-73 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| COCONUT OIL | Q9L0O73W7L | IACT |
| PALM KERNEL OIL | B0S90M0233 | IACT |
| BUTYLATED HYDROXYANISOLE | REK4960K2U | IACT |
| TERCONAZOLE | 0KJ2VE664U | ACTIB |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 3 | 2022-11-23 | full-release | 2026-05-31 20:45:14 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUPPOSITORY / VAGINAL | 1 mg | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | SOLUTION / TOPICAL | 15.5 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | CAPSULE, LIQUID FILLED / ORAL | NA | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUPPOSITORY / VAGINAL | 1 mg | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | TABLET / ORAL | NA | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | SOAP / TOPICAL | 4.6 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | SOLUTION / TOPICAL | 15.5 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | AEROSOL, FOAM / TOPICAL | 23.6 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | OINTMENT / TOPICAL | 14.75 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | SOAP / TOPICAL | 4.6 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | CAPSULE, LIQUID FILLED / ORAL | NA | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | TABLET / ORAL | NA | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | OINTMENT / TOPICAL | 14.75 %w/w | ||
| coconut oil | COCONUT OIL | Q9L0O73W7L | AEROSOL, FOAM / TOPICAL | 23.6 %w/w |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A077553-001 | TERCONAZOLE | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 |
| Application-product | TE code |
|---|---|
| A077553-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A077553-001 | TERCONAZOLE | 80MG | SUPPOSITORY / VAGINAL | AB | 2007-03-09 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A077553-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A077553-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A077553-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A077553-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A077553-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A077553-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A077553-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A077553-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A077553-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A077553-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A077553-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A077553-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A077553-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A077553-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A077553-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A077553-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A077553-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A077553-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A077553-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A077553-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A077553-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A077553-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A077553-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A077553-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A077553-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A077553-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A077553-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A077553-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A077553-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A077553-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A077553-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A077553-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A077553-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A077553-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A077553-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A077553-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A077553-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A077553-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A077553-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A077553-001 | AB | 1 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Terconazole | TERCONAZOLE | Cosette Pharmaceuticals, Inc. | 38cd1718-6b3c-415d-a17f-7b399adb0ba2 | 2026-05-07 | Warnings, Adverse reactions | 0713-0552-73 0713-0552 00713055273 513edef8-abb4-1947-e063-6394a90af7bf 38cd1718-6b3c-415d-a17f-7b399adb0ba2 |
Adverse event summaries are temporarily unavailable. Other product information remains available.
